Potential impact of new oral anticoagulants on the management of atrial fibrillation‐related stroke in primary care

Kenneth D. Harris, Jonathan MantInternational Journal of Clinical Practice 2013 · DOI

TL;DR

New oral anticoagulants (OACs) like dabigatran, rivaroxaban, and apixaban are as effective and safer than warfarin for preventing strokes in atrial fibrillation (AF) patients. These OACs are also cost-effective, offering primary care physicians a more convenient and potentially more widely adopted option for stroke prevention, especially for patients with poor warfarin control or those who dislike it.

What Problem Does This Paper Address?

Atrial fibrillation (AF) significantly increases the risk of stroke, and anticoagulation with warfarin is the established, effective treatment. However, warfarin is notoriously underused in clinical practice. This underuse stems from several factors: a high discontinuation rate, physician reluctance due to fear of bleeding (especially intracranial hemorrhage), and patient-driven concerns about the need for regular monitoring (INR), dietary restrictions, and drug interactions. This review aims to assess the effectiveness, safety, and cost-effectiveness of newer oral anticoagulants (OACs) as potential alternatives to warfarin, focusing on their implications for primary care management of AF-related stroke.

Methods

The authors conducted a literature search of MEDLINE for publications between 2007 and May 2012. They specifically looked for phase III trials of new OACs (rivaroxaban, dabigatran, and apixaban) and relevant cost-benefit analyses. The review focused on comparing these new agents to warfarin in terms of stroke and systemic embolism prevention, safety profiles, and economic viability.

Datasets

Not discussed in the paper. The paper reviews existing clinical trial data and cost-effectiveness analyses rather than introducing new datasets.

Key Insights and Ideas

  • OACs are a viable, potentially superior alternative to warfarin: The new OACs demonstrate at least non-inferiority to warfarin in preventing stroke and systemic embolism, with some showing superiority. Crucially, they also offer a reduced risk of intracranial hemorrhage, a major concern with warfarin.
  • Improved safety profile, especially regarding bleeding: While all anticoagulants carry a bleeding risk, the new OACs show a lower incidence of intracranial hemorrhage compared to warfarin. This is a significant advantage for patient safety.
  • Convenience factor is a game-changer: The once- or twice-daily dosing of OACs, without the need for routine INR monitoring, dramatically improves patient convenience and adherence compared to warfarin. This addresses a major barrier to warfarin use.
  • Cost-effectiveness supports adoption: Despite higher upfront drug costs, cost-effectiveness analyses indicate that OACs are a good investment, particularly for patients at higher risk of stroke or those with poor INR control on warfarin. The cost savings from preventing strokes outweigh the increased drug expenditure.
  • Primary care can stratify and optimize treatment: The availability of OACs allows primary care physicians to better stratify their AF patient population based on stroke risk and previous warfarin experience. This enables more targeted and effective stroke prevention strategies.

Key Results

  • Efficacy: All three new OACs (rivaroxaban, dabigatran, apixaban) were found to be at least as effective as warfarin in preventing stroke and systemic embolism in phase III trials. Apixaban and higher-dose dabigatran showed superiority in some analyses.
  • Safety:
    • Intracranial Hemorrhage: All three new OACs were associated with a lower risk of intracranial hemorrhage compared to warfarin.
  • Major Bleeding: Rivaroxaban and higher-dose dabigatran had similar major bleeding risks to warfarin, while apixaban and lower-dose dabigatran had lower risks.
  • Other Side Effects: Rates of gastrointestinal bleeding were similar or higher for OACs compared to warfarin. Rivaroxaban showed increased epistaxis and hematuria, while dabigatran showed increased dyspepsia.
  • Cost-Effectiveness: Incremental Cost-Effectiveness Ratios (ICERs) for dabigatran and rivaroxaban generally fall within acceptable ranges for healthcare systems, suggesting they are cost-effective for stroke prevention in AF patients, especially when compared to the costs of stroke itself.

Limitations and Future Work

  • Direct Cross-Trial Comparisons: The authors note that direct comparisons between the different OACs are problematic due to variations in trial designs, statistical analyses, and patient populations.
  • Long-Term Data: While phase III trials provide robust short-to-medium term data, long-term safety and effectiveness data for OACs in real-world primary care settings are still emerging.
  • Affordability vs. Cost-Effectiveness: The paper acknowledges that while OACs are cost-effective, their higher total drug cost might pose a challenge for local commissioning groups, potentially hindering their widespread adoption despite their benefits.
  • Future Work: The authors suggest that stratification of the general practice AF population by stroke risk and warfarin experience will be crucial for optimizing the introduction and use of new OACs. Further research into real-world implementation and long-term outcomes will be valuable.

Summary updated

Abstract

The clinical and economic benefits of the new oral anticoagulants, along with appropriate risk stratification, may enable a higher number of patients with AF to receive effective and convenient prophylaxis for stroke prevention.
BibTeX
@article{harris2013potential,
  author = {Kenneth D. Harris and Jonathan Mant},
  title = {{Potential impact of new oral anticoagulants on the management of atrial fibrillation‐related stroke in primary care}},
  journal = {International Journal of Clinical Practice},
  year = {2013},
  doi = {10.1111/ijcp.12177},
}
Figure